SCHEMBL3801446

SCHEMBL3801446

Cc1ccccc1C(Cl)(c1ccccc1)c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.44
ACHE P22303 3/20 0.39
KCNN4 O15554 4/20 0.38
CYP1A2 P05177 1/20 0.37
KIF11 P52732 1/20 0.36
MAPK1 P28482 1/20 0.34
GABRA1 P14867 1/20 0.34
GABRB2 P47870 1/20 0.34
ESR1 P03372 1/20 0.34
ESR2 Q92731 1/20 0.34
ALDH1A1 P00352 3/20 0.33
TAAR1 Q96RJ0 1/20 0.32
ALOX15 P16050 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA7 P43166 1/20 0.32
CA9 Q16790 1/20 0.32
LMNA P02545 1/20 0.32
ALOX12 P18054 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2484316 0.95 TSHR (0.44) TSHRACHEKCNN4CYP1A2KIF11
SCHEMBL31521772 0.85 TSHR (0.47) TSHRACHECYP1A2GABRA1GABRB2
SCHEMBL11528502 0.85 TSHR (0.47) TSHRACHECYP1A2GABRA1GABRB2
SCHEMBL2484319 0.85 TRPA1 (0.40) TSHRACHEKCNN4CYP1A2KIF11
SCHEMBL4122937 0.82 TSHR (0.44) TSHRACHEKCNN4CYP1A2KIF11
SCHEMBL11522521 0.80 CYP1A2 (0.37) TSHRACHECYP1A2KIF11LMNA
SCHEMBL16933920 0.80 TSHR (0.42) TSHRACHEKCNN4CYP1A2KIF11
SCHEMBL11624548 0.79 TSHR (0.38) TSHRACHECYP1A2KIF11ESR1
SCHEMBL11622216 0.79 MAPT (0.46) TSHRCYP1A2KIF11ESR1ESR2
SCHEMBL11524798 0.79 KIF11 (0.36) TSHRACHEKCNN4KIF11GABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113549145-B Preparation method of somatostatin 浙江湃肽生物有限公司 2023-07-25 CN claimed
CN-113549145-A Preparation method of somatostatin 浙江湃肽生物有限公司 2021-10-26 CN claimed
CN-113549145-B Preparation method of somatostatin 浙江湃肽生物有限公司 2023-07-25 CN disclosed
CN-113549145-A Preparation method of somatostatin 浙江湃肽生物有限公司 2021-10-26 CN disclosed
CN-108295030-B Bufalin micelle nanometer preparation and preparation method thereof 香港理工大学深圳研究院 2020-04-07 CN disclosed
US-10413594-B2 Conjugates of somatostatin analogues PROLYNX LLC (US) 2019-09-17 US disclosed
US-20180296648-A1 CONJUGATES OF SOMATOSTATIN ANALOGUES PROLYNX LLC (US) 2018-10-18 US disclosed
US-10086049-B2 Conjugates of somatostatin analogues PROLYNX LLC (US) 2018-10-02 US disclosed
CN-106232131-A Conjugates of somatostatin and analogs thereof 普洛林克斯有限责任公司 2016-12-14 CN disclosed
US-20160271227-A1 CONJUGATES OF SOMATOSTATIN ANALOGUES PROLYNX LLC (US) 2016-09-22 US disclosed
EP-3060230-A1 CONJUGATES OF SOMATOSTATIN AND ITS ANALOGS Prolynx LLC (US) 2016-08-31 EP disclosed
EP-2606911-A1 Receptor And Antigen Targeted Prodrug KTB Tumorforschungsgesellschaft mbH (DE) 2013-06-26 EP disclosed
EP-2604283-A1 Receptor And Antigen Targeted Prodrug KTB Tumorforschungsgesellschaft mbH (DE) 2013-06-19 EP disclosed
EP-2604284-A1 Receptor And Antigen Targeted Prodrug KTB Tumorforschungsgesellschaft mbH (DE) 2013-06-19 EP disclosed
US-20100111866-A1 Receptor and Antigen Targeted Prodrug KTB TUMORFORSCHUNGSGESELLSCHAFT MBH (DE) 2010-05-06 US disclosed
EP-2129402-A2 RECEPTOR AND ANTIGEN TARGETED PRODRUG KTB Tumorforschungsgesellschaft mbH (DE) 2009-12-09 EP disclosed
WO-2008098788-A2 RECEPTOR AND ANTIGEN TARGETED PRODRUG KTB TUMORFORSCHUNGSGESELLSCHAFT MBH (DE) 2008-08-21 WO disclosed
US-4136096-A REACTING A 3-CYANO-PENAM WITH AN AZIDE PFIZER INC. (US) 1979-01-23 US disclosed
US-4081455-A ANTIBACTERIAL PFIZER INC. (US) 1978-03-28 US disclosed
US-3992394-A PENICILLIN INTERMEDIATES FOR BACTERICIDES PFIZER INC. (US) 1976-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180296648-A1 CONJUGATES OF SOMATOSTATIN ANALOGUES SSTR4, SSTR3, SSTR2 TSHR 36/4885ACHE 1696/4885KCNN4 2372/4885
US-20160271227-A1 CONJUGATES OF SOMATOSTATIN ANALOGUES SSTR4, SSTR3, SSTR2 TSHR 36/4885ACHE 1696/4885KCNN4 2372/4885
US-10413594-B2 Conjugates of somatostatin analogues SSTR4, SSTR3, SSTR2 TSHR 36/4885ACHE 1696/4885KCNN4 2372/4885
US-10086049-B2 Conjugates of somatostatin analogues SSTR4, SSTR3, SSTR2 TSHR 36/4885ACHE 1696/4885KCNN4 2372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.